Zacks: Brokerages Anticipate Aclaris Therapeutics (ACRS) to Announce -$0.99 EPS

Wall Street brokerages expect that Aclaris Therapeutics (NASDAQ:ACRS) will announce earnings of ($0.99) per share for the current fiscal quarter, Zacks reports. Three analysts have issued estimates for Aclaris Therapeutics’ earnings. The highest EPS estimate is ($0.94) and the lowest is ($1.06). Aclaris Therapeutics posted earnings of ($0.48) per share during the same quarter last year, which indicates a negative year-over-year growth rate of 106.3%. The business is expected to announce its next earnings report on Tuesday, May 8th.

On average, analysts expect that Aclaris Therapeutics will report full year earnings of ($4.27) per share for the current financial year, with EPS estimates ranging from ($4.64) to ($3.85). For the next year, analysts forecast that the business will report earnings of ($3.32) per share, with EPS estimates ranging from ($3.89) to ($2.87). Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research firms that cover Aclaris Therapeutics.

How to Become a New Pot Stock Millionaire

Aclaris Therapeutics (NASDAQ:ACRS) last released its quarterly earnings results on Monday, March 12th. The biotechnology company reported ($0.80) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.90) by $0.10. The business had revenue of $1.00 million for the quarter, compared to analysts’ expectations of $0.80 million.

A number of equities research analysts recently issued reports on the stock. Cantor Fitzgerald set a $50.00 price target on shares of Aclaris Therapeutics and gave the company a “buy” rating in a research note on Friday. Leerink Swann cut their price objective on shares of Aclaris Therapeutics from $54.00 to $52.00 and set an “outperform” rating on the stock in a research report on Wednesday, March 28th. Zacks Investment Research upgraded shares of Aclaris Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, February 19th. Guggenheim started coverage on shares of Aclaris Therapeutics in a research report on Thursday, February 8th. They set a “buy” rating and a $53.00 price objective on the stock. Finally, BidaskClub cut shares of Aclaris Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Friday, February 2nd. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company. The stock has an average rating of “Hold” and a consensus price target of $43.50.

Aclaris Therapeutics stock traded down $0.20 during mid-day trading on Friday, reaching $16.46. 194,484 shares of the company’s stock traded hands, compared to its average volume of 322,198. The company has a market cap of $512.35, a price-to-earnings ratio of -6.58 and a beta of 1.63. Aclaris Therapeutics has a 12-month low of $16.01 and a 12-month high of $33.10.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Teachers Advisors LLC grew its holdings in shares of Aclaris Therapeutics by 8.4% in the fourth quarter. Teachers Advisors LLC now owns 42,099 shares of the biotechnology company’s stock worth $1,038,000 after purchasing an additional 3,273 shares during the last quarter. Rosenblum Silverman Sutton S F Inc. CA grew its holdings in shares of Aclaris Therapeutics by 11.1% in the fourth quarter. Rosenblum Silverman Sutton S F Inc. CA now owns 46,200 shares of the biotechnology company’s stock worth $1,139,000 after purchasing an additional 4,600 shares during the last quarter. Alps Advisors Inc. grew its holdings in shares of Aclaris Therapeutics by 15.7% in the fourth quarter. Alps Advisors Inc. now owns 34,168 shares of the biotechnology company’s stock worth $843,000 after purchasing an additional 4,626 shares during the last quarter. Cubist Systematic Strategies LLC bought a new position in shares of Aclaris Therapeutics in the third quarter worth about $142,000. Finally, Redmile Group LLC grew its holdings in shares of Aclaris Therapeutics by 6.0% in the fourth quarter. Redmile Group LLC now owns 107,020 shares of the biotechnology company’s stock worth $2,639,000 after purchasing an additional 6,060 shares during the last quarter. Hedge funds and other institutional investors own 92.19% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This news story was originally published by Ticker Report and is the property of of Ticker Report. If you are reading this news story on another domain, it was stolen and republished in violation of US & international trademark and copyright laws. The correct version of this news story can be accessed at https://www.tickerreport.com/banking-finance/3336131/zacks-brokerages-anticipate-aclaris-therapeutics-acrs-to-announce-0-99-eps.html.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc, a biopharmaceutical company, focuses on identifying, developing, and commercializing various therapies to address the unmet needs in medical and aesthetic dermatology and immunology in the United States. The company operates in two segments, Dermatology Therapeutics and Contract Research.

Get a free copy of the Zacks research report on Aclaris Therapeutics (ACRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Aclaris Therapeutics (NASDAQ:ACRS)

Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

RHFCoin Trading 3% Higher  Over Last Week
RHFCoin Trading 3% Higher Over Last Week
HomeBlockCoin Achieves Market Capitalization of $80,948.00
HomeBlockCoin Achieves Market Capitalization of $80,948.00
Comparing Ensign Group  & Genesis HealthCare
Comparing Ensign Group & Genesis HealthCare
Contrasting Moelis & Company  & The Competition
Contrasting Moelis & Company & The Competition
Financial Comparison: Intrexon  versus Sorrento Therapeutics
Financial Comparison: Intrexon versus Sorrento Therapeutics
$713.23 Million in Sales Expected for Genesis Energy, L.P.  This Quarter
$713.23 Million in Sales Expected for Genesis Energy, L.P. This Quarter


© 2006-2018 Ticker Report. Google+.